PMID- 35415826
OWN - NLM
STAT- MEDLINE
DCOM- 20230131
LR  - 20230313
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 68
IP  - 1
DP  - 2023 Jan
TI  - Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in 
      Biologic-Naive Patients with Ulcerative Colitis.
PG  - 223-232
LID - 10.1007/s10620-022-07472-1 [doi]
AB  - BACKGROUND: The comparative long-term survival of first-line biologics for UC and 
      reasons for drug discontinuation are poorly understood. We sought to compare the 
      long-term drug survival related to non-response (NR) and adverse effects (AEs) 
      for vedolizumab, adalimumab, and infliximab among biologic-naive patients with 
      UC. METHODS: This was a retrospective cohort study of adult biologic-naive 
      patients with moderate-to-severe UC initiating vedolizumab, adalimumab, or 
      infliximab 6/1/14-12/31/20 at a large academic medical center. The primary 
      outcome was time to biologic discontinuation for primary or secondary NR 
      (including colectomy). The secondary outcome was time to biologic discontinuation 
      due to AEs. Inverse probability of treatment-weighted (IPTW) Cox regression was 
      used to perform three pair-wise comparisons of drug survival. RESULTS: The cohort 
      included 805 patients with UC who initiated vedolizumab (n = 195), adalimumab 
      (n = 278), or infliximab (n = 332). The adjusted hazard of biologic 
      discontinuation for NR was significantly lower for vedolizumab vs adalimumab (HR 
      0.51, 95% CI 0.34-0.75), similar for vedolizumab vs infliximab (HR 1.32, 95% CI 
      0.79-2.18), and greater for adalimumab vs infliximab (HR 2.07, 95% CI 1.51-2.86). 
      The adjusted hazard of discontinuation for AEs was significantly lower for 
      vedolizumab vs adalimumab (HR 0.25, 95% CI 0.09-0.64), lower for vedolizumab vs 
      infliximab (HR 0.21, 95% CI 0.10-0.46), and similar for adalimumab vs infliximab 
      (HR 0.85, 95% CI 0.53-1.35). CONCLUSIONS: There was greater survival of 
      vedolizumab compared to adalimumab for clinical response and greater survival of 
      vedolizumab compared to both adalimumab and infliximab for AEs. These long-term 
      data support the use of vedolizumab as a first-line biologic over adalimumab for 
      biologic-naive patients with UC.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Dalal, Rahul S
AU  - Dalal RS
AD  - Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, 
      Brigham and Women's Hospital, Harvard Medical School, 850 Boylston Street, Suite 
      201, Chestnut Hill, Boston, MA, 02467, USA.
FAU - McClure, Emma L
AU  - McClure EL
AD  - Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, 
      Brigham and Women's Hospital, Harvard Medical School, 850 Boylston Street, Suite 
      201, Chestnut Hill, Boston, MA, 02467, USA.
FAU - Marcus, Jenna
AU  - Marcus J
AD  - Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, 
      Brigham and Women's Hospital, Harvard Medical School, 850 Boylston Street, Suite 
      201, Chestnut Hill, Boston, MA, 02467, USA.
FAU - Allegretti, Jessica R
AU  - Allegretti JR
AUID- ORCID: 0000-0003-3585-2425
AD  - Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, 
      Brigham and Women's Hospital, Harvard Medical School, 850 Boylston Street, Suite 
      201, Chestnut Hill, Boston, MA, 02467, USA. jallegretti@bwh.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220412
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - FYS6T7F842 (Adalimumab)
RN  - B72HH48FLU (Infliximab)
RN  - 9RV78Q2002 (vedolizumab)
RN  - 0 (Biological Products)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Adalimumab/adverse effects
MH  - Infliximab/adverse effects
MH  - *Colitis, Ulcerative/diagnosis/drug therapy/chemically induced
MH  - Retrospective Studies
MH  - *Biological Products
OTO - NOTNLM
OT  - Anti-TNF
OT  - Anti-integrin
OT  - Failure
OT  - Inflammatory bowel disease
OT  - Remission
OT  - Survival
EDAT- 2022/04/14 06:00
MHDA- 2023/02/01 06:00
CRDT- 2022/04/13 05:38
PHST- 2022/02/02 00:00 [received]
PHST- 2022/03/01 00:00 [accepted]
PHST- 2022/04/14 06:00 [pubmed]
PHST- 2023/02/01 06:00 [medline]
PHST- 2022/04/13 05:38 [entrez]
AID - 10.1007/s10620-022-07472-1 [pii]
AID - 10.1007/s10620-022-07472-1 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2023 Jan;68(1):223-232. doi: 10.1007/s10620-022-07472-1. Epub 2022 
      Apr 12.